<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83186">
  <stage>Registered</stage>
  <submitdate>19/09/2008</submitdate>
  <approvaldate>5/12/2008</approvaldate>
  <actrnumber>ACTRN12608000610336</actrnumber>
  <trial_identification>
    <studytitle>Dexamphetamine modulation of brainwave activity and prepulse inhibition in healthy participants</studytitle>
    <scientifictitle>Dexamphetamine modulation of brainwave activity and prepulse inhibition in healthy participants</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>0.45 mg/kg (oral) dose of dexamphetamine administered once</interventions>
    <comparator>placebo (oral glucose capsule) administered once. This is a cross-over trial with a 
minimum wash-out between drug and placebo is 5 days, maximum washout is 14 days, mode (most frequent) wash-out is 7 days.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Prepulse Inhibition of the Acoustic Startle Response</outcome>
      <timepoint>90-120 min</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in P300 Event-Related Potential (EEG)</outcome>
      <timepoint>210 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Saliva dexamphetamine level</outcome>
      <timepoint>0, 90, 150, 240, 300 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma dexamphetamine level</outcome>
      <timepoint>90 min</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>healthy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Pregnancy or currently breastfeeding
2. hearing disorders
3. neurological disorders or known seizure risk
4. history of loss of consciousness for over 15 min
5. current diagnosis or treatment for a mental illness
6. past or current treatment for substance use disorder
7. significant risk of psychosis
8. presence or history of a kinetic disorder
9. presence or history of hypertension
10. presence or history of hepatic insufficiency
11. presence renal insufficiency
12. presence or history of cardiovascular disorder
13. significant risk of suicide
14. known hypersensitivity to amphetamines
15. receiving any systemic prescription medication (excluding contraceptives)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>This is a within-subject treatment design (AB) where the order of treatment (placebo or drug) is randomised. The person who determines eligibility for inclusion in the trial is unaware of the treatment being allocated on the day of assessment and medical examination. Allocation of order of treatment was randomised by the Participant is provided information on the study and by an experimenter who is blind to the allocation. Interview and medical examination and decision to include or exclude from the study is conducted by one of two Psychiatrists who are unaware of the allocation to treatment schedule. initial contact Chief Investigator (MMI) off-site with a random number table, who does not assess the participants' suitability, does not test the participants, or analyse the data.</concealment>
    <sequence>Simple randomisation of treatment order by random number table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>2/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Mathew Martin-Iverson</primarysponsorname>
    <primarysponsoraddress>University of Western Australia
35 Stirling Highway, Crawley, WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Australia</fundingname>
      <fundingaddress>35 Stirling Highway
Crawley, WA 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Joseph Lee</sponsorname>
      <sponsoraddress>Graylands Hospital,
Brockway Road
Mt Claremont, WA 6600</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Rajan Iyyalol</othercollaboratorname>
      <othercollaboratoraddress>Graylands Hospital
Brockway Road
Mt Claremont, WA 6600</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Rajan Iyyalol</othercollaboratorname>
      <othercollaboratoraddress>Graylands Hospital,
Brockway Road
Mt Claremont, WA 6600</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to determine whether or not acute administration of amphetamine produces schizophrenic-like brain function and cognitive effects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Western Australia Human Research Ethics Committee</ethicname>
      <ethicaddress>35 Stirling Highway
Crawley, WA 6009</ethicaddress>
      <ethicapprovaldate>26/03/2008</ethicapprovaldate>
      <hrec>RA/4/1/1987</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mathew Martin-Iverson</name>
      <address>University of Western Australia
Pharmacology M510,
35 Stirling Highway,
Crawley, WA 6009</address>
      <phone>(08) 9347-6443</phone>
      <fax>(08) 9346-3469</fax>
      <email>mathew.martin-Iverson@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mathew Martin-Iverson</name>
      <address>University of Western Australia
Pharmacology M510,
35 Stirling Highway,
Crawley, WA 6009</address>
      <phone>(08)-9347-6443</phone>
      <fax>(08)-9346-3469</fax>
      <email>mathew.martin-iverson@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mathew Martin-Iverson</name>
      <address>University of Western Australia
Pharmacology M510,
35 Stirling Highway,
Crawley, WA 6009</address>
      <phone>(08) 9347-6443</phone>
      <fax>(08) 9345-3469</fax>
      <email>mathew.martin-iverson@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>